消化性溃疡后幽门螺杆菌根除治疗的时间延迟与复发性溃疡、溃疡不良事件及胃癌风险:一项基于人群的队列研究
这项瑞典全国性基于人群的队列研究纳入2005至2013年间因消化性溃疡病接受幽门螺杆菌根除治疗的29,032例患者,分析溃疡诊断至根除治疗间期与复发性溃疡、复杂性溃疡及胃癌风险的关系。与7天内根除相比,延迟8至30天起复发性溃疡风险即升高,且随延迟延长呈时间依赖性增加;复杂性溃疡风险增幅更大;胃癌风险在延迟超过60天后升高。
要点
- 与溃疡诊断后7天内根除相比,延迟8至30天根除的复发性溃疡HR为1.17(95%CI 1.08-1.25)。
- 延迟31至60天、61至365天及超过365天根除的复发性溃疡HR分别为2.37、2.96和3.55。
- 复杂性溃疡风险随延迟增加更明显,延迟超过365天根除的HR为6.14(95%CI 5.47-6.89)。
核心结论
- 消化性溃疡诊断后延迟幽门螺杆菌根除治疗会时间依赖性增加复发性溃疡风险,对复杂性溃疡风险增加更明显,从延迟8至30天即开始。
研究设计与样本
- 瑞典全国性基于人群的队列研究,纳入2005至2013年间因消化性溃疡病接受幽门螺杆菌根除治疗的29,032例患者。
- 分析溃疡诊断日期与根除治疗日期之间预设时间间期与研究结局的关系,采用Cox回归提供风险比(HR)及95%置信区间(95%CI),并校正年龄、性别、合并症、溃疡病史、致溃疡药物使用及质子泵抑制剂(PPI)使用。
主要发现
- 与溃疡诊断后7天内根除治疗相比,延迟8至30天、31至60天、61至365天及超过365天根除治疗的复发性溃疡HR分别为1.17(95%CI 1.08-1.25)、2.37(95%CI 2.16-2.59)、2.96(95%CI 2.76-3.16)和3.55(95%CI 3.33-3.79)。
- 与溃疡诊断后7天内根除治疗相比,延迟8至30天、31至60天、61至365天及超过365天根除治疗的复杂性溃疡HR分别为1.55(95%CI 1.35-1.78)、3.19(95%CI 2.69-3.78)、4.00(95%CI 3.51-4.55)和6.14(95%CI 5.47-6.89)。
- 与溃疡诊断后7天内根除治疗相比,延迟8至30天、31至60天、61至365天及超过365天根除治疗的胃癌HR分别为0.85(95%CI 0.32-2.23)、1.31(95%CI 0.31-5.54)、3.64(95%CI 1.55-8.56)和4.71(95%CI 2.36-9.38)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Helicobacter pylori is associated with peptic ulcer disease and gastric cancer. Therefore we wanted to test how various lengths of delays in H pylori eradication therapy influence the risk of recurrent peptic ulcer, ulcer adverse events, and gastric cancer. METHODS: This population-based nationwide Swedish cohort study included 29,032 patients receiving H pylori eradication therapy after peptic ulcer disease in 2005 to 2013. Predefined time intervals between date of peptic ulcer diagnosis and date of eradication therapy were analyzed in relation to study outcomes. Cox regression provided hazard ratios (HRs) and 95% confidence intervals (95% CIs), adjusted for age, sex, comorbidity, history of ulcer disease, use of ulcerogenic drugs, and use of proton pump inhibitors (PPIs). RESULTS: Compared with eradication therapy within 7 days of peptic ulcer diagnosis, eradication therapy within 8 to 30, 31 to 60, 61 to 365, and >365 days corresponded with HRs of recurrent ulcer of 1.17 (95% CI, 1.08-1.25), 2.37 (95% CI, 2.16-2.59), 2.96 (95% CI, 2.76-3.16), and 3.55 (95% CI, 3.33-3.79), respectively. The corresponding HRs for complicated ulcer were 1.55 (95% CI, 1.35-1.78), 3.19 (95% CI, 2.69-3.78), 4.00 (95% CI, 3.51-4.55), and 6.14, (95% CI, 5.47-6.89), respectively. For gastric cancer the corresponding HRs were .85 (95% CI, .32-2.23), 1.31 (95% CI, .31-5.54), 3.64 (95% CI, 1.55-8.56), and 4.71 (95% CI, 2.36-9.38), respectively. CONCLUSIONS: Delays in H pylori eradication therapy after peptic ulcer diagnosis time-dependently increase the risk of recurrent ulcer, even more so for complicated ulcer, starting from delays of 8 to 30 days.
引用
- Sverdén E, Brusselaers N, Wahlin K, et al. Time latencies of Helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer, ulcer adverse events, and gastric cancer: a population-based cohort study. Gastrointest Endosc. 2017. PMID: 29233672. doi:10.1016/j.gie.2017.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。